Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Conditions

• Metastatic Nonsmall Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — DRUG
  Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.

Study Details

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

Key Dates

Start date

Jan 22, 2024

Status verified

Feb 2026

Primary completion

Jan 31, 2027

Completion

Jan 31, 2027

Study Design

Enrollment

40 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: [177Lu]Lu DOTA-ABM-5G single dose therapy study
  Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy.

Primary Outcome Measure

[68Ga]Ga DOTA-5G PET/CT imaging [ Time Frame: 2 hours from time of injection ]

Central Contacts

• Julie L Sutcliffe, Phd
  9167345536
  [email protected]

Locations (1)

Find similar trials in Sacramento, CA